The company began executing this strategy through a deal with a new company, Aurora Biosciences, which has novel technology for high throughput drug screening. The acquisition of NemaPharm, a company with C. elegans worm technology, agreements with two key fruit fly geneticists at the University of California, San Diego, and an agreement with GenPharm, a transgenic mouse company, will help Sequana scientists to understand the molecular pathways through which disease-causing genes operate. These pathways can then be used to screen for therapeutic compounds that treat the cause of a disease, rather than just its symptoms. We believe that Sequana's acquisitions of technologies to translate genes into drugs demonstrates an excellent grasp of the strategic issues in the genomics business. This page only represents the views of the author and should in no way be taken as professional investment advice.
Stocks can go down as well as up.
Any investment should only be made after careful analysis of the company and the current economic conditions.